Rabeprazole Sodium DR
Closed Solicitation Posted
This opportunity was awarded. See its 2 award notices in the notice history.
- Solicitation number
- SPE2D2-25-R-0006
- Agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency Troop Support Medical is seeking a national contract for Rabeprazole Sodium Delayed Release 20MG Tablets through solicitation SPE2D2-25-R-0006. The procurement aims to supply pharmaceutical tablets in three package sizes (30-count, 90-count, and 500-count bottles) for multiple federal agencies including the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. This is a lowest price technically acceptable (LPTA) procurement with a base year and four option years, meaning cost will be a primary evaluation factor. Offerors must submit comprehensive documentation including FDA compliance information, manufacturing facility details, and past performance history by May 15, 2025, at 3:00 PM EST through the Defense Logistics Agency Internet Bid Board System (DIBBS). Specific requirements include unit-of-use packaging, child-proof closures, and bar code labeling, with contractors expected to meet stringent pharmaceutical manufacturing standards.
There are no specific set-aside designations for this solicitation, making it open to all qualified pharmaceutical manufacturers in the NAICS 325412 category. The estimated annual quantities include 13,378 bottles of 30-count, 28,973 bottles of 90-count, and 10,010 bottles of 500-count packaging, representing a significant national pharmaceutical supply contract. Distribution will be managed through Pharmaceutical Prime Vendors, with a mandatory 0.5% cost recovery fee included in the contract terms. The contract will have a total potential duration of five years, with contractors required to submit quarterly sales reports and comply with federal contracting regulations. While specific award values are not explicitly stated, the multi-year contract and substantial annual quantities suggest a potentially lucrative opportunity for pharmaceutical manufacturers capable of meeting the rigorous technical and compliance requirements outlined in the solicitation.
Notice text
Solicitation attached.
Files
| File | Type | Posted |
|---|---|---|
| SPE2D2-25-R-0006 Solicitation - Rabeprazole Final.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Rabeprazole Sodium DR - Award | Award Notice | |
| Pharm Manuf/Distr Div - FSA | Award Notice | |
| This notice | Solicitation | |
| Rabeprazole Sodium DR | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Methylphenidate ER | Medical Supply Chain | No set-aside | |
| 6505--Sodium Bicarbonate Injection Vial Restricted to Made in America | National Acquisition Center | No set-aside | |
| 6505--Imatinib Tablets | National Acquisition Center | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity